Aspirin and colorectal cancer: the promise of precision chemoprevention

Aspirin (acetylsalicylic acid) has become one of the most commonly used drugs, given its role as an analgesic, antipyretic and agent for cardiovascular prophylaxis. Several decades of research have provided considerable evidence demonstrating its potential for the prevention of cancer, particularly colorectal cancer. Broader clinical recommendations for aspirin-based chemoprevention strategies have recently been established; however, given the known hazards of long-term aspirin use, larger-scale adoption of an aspirin chemoprevention strategy is likely to require improved identification of individuals for whom the protective benefits outweigh the harms. Such a precision medicine approach may emerge through further clarification of aspirin's mechanism of action.

[1]  Steven Gallinger,et al.  Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24 , 2007, Nature Genetics.

[2]  A. Zauber,et al.  The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma , 2011, Cancer Prevention Research.

[3]  L. Marton,et al.  Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases , 2007, Nature Reviews Drug Discovery.

[4]  R. Morgenstern,et al.  Microsomal glutathione transferase 1: mechanism and functional roles , 2011, Drug metabolism reviews.

[5]  N. Habermann,et al.  Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. , 2014, Carcinogenesis.

[6]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[7]  D. Schaid,et al.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. , 2001, American journal of human genetics.

[8]  V. Fuster,et al.  Aspirin: A Historical and Contemporary Therapeutic Overview , 2011, Circulation.

[9]  T. Yeatman,et al.  Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation , 2015, Acta oncologica.

[10]  J. Manson,et al.  Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study , 1998, Annals of Internal Medicine.

[11]  A. Tenesa,et al.  Effect of aspirin and NSAIDs on risk and survival from colorectal cancer , 2010, Gut.

[12]  Gianni Tognoni,et al.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.

[13]  Patrick T. Bradshaw,et al.  Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS) , 2015, Cancer Prevention Research.

[14]  C Warlow,et al.  The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[15]  M. Bertagnolli,et al.  15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors , 2009, Proceedings of the National Academy of Sciences.

[16]  E. Gerner,et al.  Polyamines and cancer: old molecules, new understanding , 2004, Nature Reviews Cancer.

[17]  N. Rifai,et al.  Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies , 2015, Cancer Causes & Control.

[18]  D. Cameron,et al.  ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours , 2016, Contemporary clinical trials.

[19]  T. Willson,et al.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[21]  C. Hutter,et al.  Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants , 2015 .

[22]  Jo-Fen Liu,et al.  Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention , 2008, Clinical Cancer Research.

[23]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[24]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[25]  M. Thun,et al.  The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.

[26]  S. Narumiya,et al.  Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. , 2015, Cancer research.

[27]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[28]  X. Ye,et al.  Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies , 2014, British Journal of Cancer.

[29]  P. Kuppen,et al.  Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. , 2014, JAMA internal medicine.

[30]  E. E. Gresch Genetic Alterations During Colorectal-Tumor Development , 1989 .

[31]  Jo-Fen Liu,et al.  Polymorphisms in PTGS1, PTGS2 and IL‐10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial , 2007, International journal of cancer.

[32]  S. Narumiya,et al.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice , 2001, Nature Medicine.

[33]  D. Buist,et al.  Aspirin Use for the Prevention of Colorectal Cancer , 2015 .

[34]  C. Ulrich,et al.  CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment , 2012, Cancer Causes & Control.

[35]  Jeannette Bigler,et al.  Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.

[36]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[37]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[38]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[39]  S. Baek,et al.  The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. , 2013, Biochemical pharmacology.

[40]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[41]  Feng Yang,et al.  Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2009, The New England journal of medicine.

[42]  D. Dixon,et al.  Mechanistic aspects of COX-2 expression in colorectal neoplasia. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[43]  C. Carlson,et al.  Genetic Variation in Prostaglandin E2 Synthesis and Signaling, Prostaglandin Dehydrogenase, and the Risk of Colorectal Adenoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[44]  J. Morrow,et al.  Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. , 2006, The Journal of clinical investigation.

[45]  E. Giovannucci,et al.  Urinary PGE-M Levels Are Associated with Risk of Colorectal Adenomas and Chemopreventive Response to Anti-Inflammatory Drugs , 2014, Cancer Prevention Research.

[46]  D. Kerr,et al.  Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Zauber,et al.  Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. , 2009, Gastroenterology.

[48]  Y. Collan,et al.  High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. , 2013, Anticancer research.

[49]  M. Hull Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? , 2005, European journal of cancer.

[50]  G. Meijer,et al.  Serrated neoplasia—role in colorectal carcinogenesis and clinical implications , 2015, Nature Reviews Gastroenterology &Hepatology.

[51]  A. Neugut,et al.  Recurrence rates for colorectal polyps , 1985, Cancer.

[52]  B C Morson,et al.  The evolution of colorectal carcinoma. , 1984, Clinical radiology.

[53]  Han Wu,et al.  Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis , 2014, Gut.

[54]  E. Giovannucci,et al.  A prospective study of plasma inflammatory markers and risk of colorectal cancer in men , 2013, British Journal of Cancer.

[55]  E. Whitlock,et al.  Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms , 2015 .

[56]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[57]  J. Baron,et al.  Cyclooxygenase-2 Polymorphisms, Aspirin Treatment, and Risk for Colorectal Adenoma Recurrence—Data from a Randomized Clinical Trial , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[58]  P. Roderick,et al.  The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. , 1993, British journal of clinical pharmacology.

[59]  L. Perdue,et al.  Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. , 2022, JAMA.

[60]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[61]  L. Chew,et al.  Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. , 2014, Anticancer research.

[62]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[63]  W. Zheng,et al.  Urinary Prostaglandin E2 Metabolite and Risk for Colorectal Adenoma , 2011, Cancer Prevention Research.

[64]  A. Algra,et al.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.

[65]  Á. Lanas,et al.  Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[66]  P. Rothwell,et al.  Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview , 2011, Cancer Prevention Research.

[67]  S. Narumiya,et al.  Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.

[68]  R. Murphy,et al.  The role of PGE2 in intestinal inflammation and tumorigenesis. , 2015, Prostaglandins & other lipid mediators.

[69]  C. Ulrich,et al.  Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1 , 2012, Pharmacogenetics and genomics.

[70]  J. Morrow,et al.  Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. , 2004, Analytical biochemistry.

[71]  E. Rimm,et al.  Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.

[72]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[73]  Ross J. Harris,et al.  Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis , 2009, Cancer Causes & Control.

[74]  R. Armstrong,et al.  Location of inhibitor binding sites in the human inducible prostaglandin E synthase, MPGES1. , 2011, Biochemistry.

[75]  E. Giovannucci,et al.  A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. , 2014, Journal of the National Cancer Institute.

[76]  Molin Wang,et al.  Aspirin use and risk of colorectal cancer according to BRAF mutation status. , 2013, JAMA.

[77]  C. Patrono,et al.  Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. , 2015, Biochimica et biophysica acta.

[78]  D. Rosenberg,et al.  mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". , 2010, Biochimie.

[79]  Rajnish A. Gupta,et al.  Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth , 2004, Nature Medicine.

[80]  K. Druey,et al.  Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.

[81]  L. Laine,et al.  Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006, The American journal of medicine.

[82]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[83]  B. Rigas,et al.  NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis. , 2006, Carcinogenesis.

[84]  J. Hurley,et al.  The molecular genetics of colorectal cancer , 2013, Frontline Gastroenterology.

[85]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[86]  J. Gaziano,et al.  Low-Dose Aspirin in the Primary Prevention of Cancer. The Women’s Health Study: A Randomized Controlled Trial , 2005 .

[87]  Stephen Senn,et al.  Gastrointestinal Adverse Effects of Short-Term Aspirin Use: A Meta-Analysis of Published Randomized Controlled Trials , 2013, Drugs in R&D.

[88]  Y. Loke,et al.  Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis , 2000, BMJ : British Medical Journal.

[89]  E. Giovannucci,et al.  Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of 15-Hydroxyprostaglandin Dehydrogenase (HPGD) , 2014, Science Translational Medicine.

[90]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[91]  K. Muir,et al.  Aspirin and folic acid for the prevention of recurrent colorectal adenomas. , 2008, Gastroenterology.

[92]  Edward S. Kim,et al.  Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial , 2008, Cancer Prevention Research.

[93]  S. Narumiya,et al.  Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. , 1999, Cancer research.

[94]  J. Potter,et al.  Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial , 2015, BMC Medical Genetics.

[95]  R. Pearson Inflammatory Markers Are Associated With Risk of Colorectal Cancer and Chemopreventive Response to Anti-Inflammatory Drugs , 2011 .

[96]  Deepak L. Bhatt,et al.  Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. , 2005, The American journal of cardiology.

[97]  J. Bigby,et al.  Goodman and Gillman's The Pharmacological Basis of Therapeutics , 1992 .

[98]  B. Leggett,et al.  The serrated pathway to colorectal carcinoma: current concepts and challenges , 2013, Histopathology.

[99]  David Reich,et al.  A common genetic risk factor for colorectal and prostate cancer , 2007, Nature Genetics.

[100]  M. Gala,et al.  Genetics of the Serrated Pathway to Colorectal Cancer , 2015, Clinical and Translational Gastroenterology.

[101]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[102]  L. Zon,et al.  Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration , 2009, Cell.

[103]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[104]  E. Giovannucci,et al.  Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. , 2011, Gastroenterology.

[105]  J. Willis,et al.  Inactivating Mutation in the Prostaglandin Transporter Gene, SLCO2A1, Associated with Familial Digital Clubbing, Colon Neoplasia, and NSAID Resistance , 2014, Cancer Prevention Research.

[106]  D. Alberts,et al.  Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[107]  D. Richel,et al.  Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A , 2006, Oncogene.

[108]  T. P. Pretlow,et al.  15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis , 2006, Proceedings of the National Academy of Sciences.

[109]  J. Little,et al.  Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. , 2003, Gastroenterology.

[110]  H. Pommergaard,et al.  Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. , 2016, Gastroenterology.

[111]  J. Zell,et al.  Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. , 2010, Journal of the National Cancer Institute.

[112]  B. Yawn,et al.  Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2007, Annals of Internal Medicine.

[113]  R. DuBois,et al.  Urinary PGE-M: A Promising Cancer Biomarker , 2013, Cancer Prevention Research.

[114]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[115]  D. D. Billheimer,et al.  Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[116]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[117]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[118]  S. Kudo,et al.  The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial , 2014, Gut.

[119]  Oliver Sieber,et al.  A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21 , 2007, Nature Genetics.

[120]  L F Watson,et al.  Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.

[121]  Elizabeth L. Barry,et al.  Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. , 2006, Journal of the National Cancer Institute.

[122]  Elizabeth L. Barry,et al.  Variants Downstream of the Ornithine Decarboxylase Gene Influence Risk of Colorectal Adenoma and Aspirin Chemoprevention , 2011, Cancer Prevention Research.

[123]  N. Cook,et al.  Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial , 2013, Annals of Internal Medicine.

[124]  K. Schrör Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. , 2011, Best practice & research. Clinical gastroenterology.

[125]  G. S. Ranger Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. , 2014, Anticancer research.

[126]  Jacques Van Dam,et al.  Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions , 2015, Clinical Cancer Research.

[127]  J. Hamilton,et al.  The TGF-β superfamily cytokine, MIC-1/GDF15: A pleotrophic cytokine with roles in inflammation, cancer and metabolism , 2011, Growth factors.

[128]  M. Gala,et al.  Molecular Pathways: Aspirin and Wnt Signaling—A Molecularly Targeted Approach to Cancer Prevention and Treatment , 2014, Clinical Cancer Research.

[129]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[130]  P. Rothwell,et al.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.

[131]  N. Habermann,et al.  Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[132]  A. Montgomery,et al.  A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial , 2013, Trials.

[133]  T. Hartman,et al.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions , 2014, Genes, chromosomes & cancer.

[134]  J. Barrett,et al.  No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPAR&ggr; act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma , 2005, Pharmacogenetics and genomics.

[135]  F. Sinicrope,et al.  Aspirin and Colorectal Cancer: Back to the Future , 2013, Clinical Cancer Research.

[136]  Young-Joon Kim,et al.  Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[137]  J. Cuzick,et al.  Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population , 2014, European Journal of Epidemiology.

[138]  Aung Ko Win,et al.  Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry , 2014, Genes, chromosomes & cancer.

[139]  S. Dey,et al.  Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ , 2004 .

[140]  R. Langenbach,et al.  Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. , 2000, Cancer research.

[141]  G. Casey,et al.  No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. , 2009, World journal of gastroenterology.

[142]  David A. Drew,et al.  Colorectal polyp prevention by daily aspirin use is abrogated among active smokers , 2015, Cancer Causes & Control.

[143]  T. Eide,et al.  Natural history of adenomas , 2005, World Journal of Surgery.

[144]  C. Carlson,et al.  Polymorphisms predicted to alter function in Prostaglandin E2 synthase and Prostaglandin E2 receptors , 2007, Pharmacogenetics and genomics.

[145]  Peter Kraft,et al.  Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. , 2013, Journal of the National Cancer Institute.

[146]  J. Meyerhardt,et al.  Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. , 2015, Journal of the National Cancer Institute.

[147]  M. Schuler Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.

[148]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[149]  Laura K. Bianchi,et al.  Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin , 2015, Gut.

[150]  Miki Ohira,et al.  LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. , 2005, Cancer research.

[151]  R. Wender Aspirin and NSAID chemoprevention, gene-environment interactions, and risk of colorectal cancer. , 2015, JAMA.

[152]  Vadim Backman,et al.  Association between rectal optical signatures and colonic neoplasia: potential applications for screening. , 2009, Cancer research.

[153]  E. Gerner,et al.  Combination Chemoprevention for Colon Cancer Targeting Polyamine Synthesis and Inflammation , 2009, Clinical Cancer Research.

[154]  N. Rothman,et al.  Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  Charles J. Kahi,et al.  ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010, The American Journal of Gastroenterology.

[156]  G. Thomas,et al.  Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. , 1994, Gut.

[157]  M. Rawlins,et al.  Prophylactic aspirin and risk of peptic ulcer bleeding , 1995, BMJ.